Vetr upgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a buy rating to a strong-buy rating in a research note published on Monday. Vetr currently has $187.82 target price on the life sciences company’s stock.

A number of other research firms also recently issued reports on ILMN. Evercore ISI reaffirmed a hold rating and issued a $139.00 target price on shares of Illumina in a research report on Tuesday, January 10th. Cowen and Company reissued an outperform rating and set a $150.00 price target on shares of Illumina in a research report on Wednesday, January 11th. Leerink Swann reissued a market perform rating and set a $132.00 price target (up previously from $114.00) on shares of Illumina in a research report on Wednesday, January 11th. Canaccord Genuity reissued a hold rating and set a $150.00 price target on shares of Illumina in a research report on Tuesday, February 21st. Finally, Cantor Fitzgerald reissued a neutral rating and set a $155.00 price target on shares of Illumina in a research report on Thursday, January 12th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $161.22.

Shares of Illumina (NASDAQ:ILMN) opened at 175.29 on Monday. Illumina has a 52-week low of $119.37 and a 52-week high of $186.88. The stock has a market cap of $25.64 billion, a PE ratio of 57.10 and a beta of 0.79. The company’s 50-day moving average price is $169.47 and its 200-day moving average price is $152.27.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.03. The business had revenue of $619 million for the quarter, compared to the consensus estimate of $612.50 million. Illumina had a return on equity of 22.89% and a net margin of 19.31%. Illumina’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.81 earnings per share. Analysts expect that Illumina will post $3.64 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Upgraded at Vetr Inc.” was first published by Marea Informative and is owned by of Marea Informative. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at http://www.mareainformativa.com/illumina-inc-ilmn-actualizado-fuerte-comprar-por-vetr-inc/108948/.

In other news, Director A Blaine Bowman sold 3,000 shares of the stock in a transaction on Wednesday, April 12th. The stock was sold at an average price of $172.72, for a total value of $518,160.00. Following the completion of the transaction, the director now directly owns 18,704 shares in the company, valued at approximately $3,230,554.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Omead Ostadan sold 259 shares of the stock in a transaction on Monday, January 30th. The shares were sold at an average price of $160.90, for a total value of $41,673.10. Following the completion of the transaction, the executive vice president now owns 27,949 shares of the company’s stock, valued at $4,496,994.10. The disclosure for this sale can be found here. Insiders sold a total of 12,476 shares of company stock valued at $2,078,440 over the last quarter. 1.60% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Baillie Gifford & Co. increased its stake in Illumina by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 18,766,712 shares of the life sciences company’s stock worth $2,402,890,000 after buying an additional 178,559 shares during the last quarter. Capital Research Global Investors increased its stake in Illumina by 2.1% in the third quarter. Capital Research Global Investors now owns 13,360,554 shares of the life sciences company’s stock worth $2,427,078,000 after buying an additional 275,483 shares during the last quarter. Edgewood Management LLC increased its stake in Illumina by 33.6% in the fourth quarter. Edgewood Management LLC now owns 6,639,776 shares of the life sciences company’s stock worth $850,157,000 after buying an additional 1,671,293 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Illumina by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,632,576 shares of the life sciences company’s stock worth $841,554,000 after buying an additional 140,411 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Illumina by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,877,155 shares of the life sciences company’s stock worth $704,324,000 after buying an additional 41,792 shares during the last quarter. Institutional investors and hedge funds own 92.79% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

5 Day Chart for NASDAQ:ILMN

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.